GlassScriptPhysician profile
Matthew David Fullmer
NPI 1841786829
$887.36
in general payments reported to CMS, 2019-2025
10 companies · $73.70 in 2025
The $73.70 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.67 · 2021: $44.52 · 2022: $322 · 2023: $214 · 2024: $192 · 2025: $73.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354 · Consulting Fee: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.44 |
| Consulting Fee | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $208.52 | 2022 | |
| Abbvie INC. | $181.05 | 2023-2025 | |
| Rxsight INC | $125.00 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $91.68 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Glaukos Corporation | $76.54 | 2022-2025 | Istent Infinite |
| Aerie Pharmaceuticals, INC. | $66.71 | 2020-2021 | |
| Sight Sciences, INC. | $60.00 | 2022-2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $38.63 | 2022 | |
| Amgen INC. | $19.75 | 2025 | Tepezza |
| Alimera Sciences, INC. | $19.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fullmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.